Back To Search Instructions
Protocols
23 protocols meet the specified criteria
Disease Site: Any Site
Protocol No.TitleStatus
0300000620Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries (1991-0002)Open
0600000609Arizona Cancer Center Biospecimen RepositoryOpen
0800000473ACCRN07: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)Open
1100000017COG AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma Not Open
1200000138Biospecimen Repository for Individuals at High Risk for Breast, Ovarian, or Other Hereditary CancersOpen
1200000177COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789,NSC#606869)in the Very High StratumOpen
1300000043Effects of Heavy Metal Exposure on DNA RepairOpen
1300000173Research Retention Strategies for Cancer Survivorship Studies: A Survey of Participant OpinionsOpen
1300000725A Cardiac Safety Study of TH-302 in Patients with Advanced Solid TumorsNot Open
1403269898Clinical study of the effect of combined treatment of aspirin and zileuton on biomarkers of tobacco-related carcinogenesis in current smokers Open
1408439554A Phase II Randomized Study of Short-Term Dexamethasone Versus Placebo in Patients Receiving Radiation Alone or Radiation and Chemotherapy for the Treatment of Head and Neck and Non-Small Cell Lung CancersOpen
1502660379S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel ObstructionOpen
1502661845A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the treatment of multiple Metastases (NRG-BR001)Open
1504814936AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing SarcomaOpen
1509106328ALTE11C2: Health Effects after Anthracycline and Radiation Therapy: Dexrazoxane and Prevention of Anthracycline-related CardiomyopathyOpen
1509136789ALTE05N1: Umbrella Long-Term Follow-Up ProtocolOpen
1605600303Isolation and Characterization of Circulating Tumor Cells (CTCs)Open
1606619215An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerOpen
1608779834A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced MalignanciesOpen
1612049078A Phase I Multicenter, Open Label Study of Enadenotucirev Combined with PD-1 Inhibitor in Subjects with Metastatic or Advanced Epithelial TumorsOpen
2002-0063Protocol for a Research Database For Hematopoieitc Stem Cell Transplantation and Marrow Toxic InjuriesOpen
25207Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients Open
PHXE-16-0073-80-15A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 (PD-1), AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES, IN PATIENTS WITH ADVANCED MALIGNANCIESOpen